ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Health Technology

Dr. Reddy's Laboratories Ltd.

Business Summary

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services and Active Ingredients, Proprietary Products, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services and Active Ingredients segment is comprised of manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API or bulk drugs, which are principal ingredients for finished pharmaceutical products. The Proprietary Products segment focuses on research, development, and manufacture of differentiated formulations and new chemical entities. The Others segment includes the operations of the wholly-owned subsidiary of the company, Aurigene Discovery Technologies Limited, a discovery stage biotechnology company developing novel and best-in-class therapies in the fields of oncology and inflammation and which works with pharmaceutical and biotechnology companies in early-stage collaborations, brining drug candidates for pre-clinical development. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.

Financial Highlights

Mar 2021 INRUSD
Gross Profit103,077M1,388.52M
Operating income31,977M430.75M
Income before tax27,844M375.07M
Net income19,149M257.95M
Diluted EPS115.141.55
Dividends Per Share250.33
Total Assets265,491M3,631.20M
Total liabilities90,510M1,237.93M
Total equity174,981M2,393.27M
Operating cash flow35,602M479.58M
Currency in INRCurrency in USD

Historical Data

 Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021
Revenue 140,809M 142,028M 153,851M 174,600M 189,722M
Gross Profit 73,531M 71,189M 78,008M 88,078M 103,077M
Operating income 12,878M 11,182M 19,584M 28,637M 31,977M
Income before tax 14,304M 13,997M 22,005M 17,471M 27,844M
Net income 12,039M 9,806M 18,795M 19,498M 19,149M
EBITDA 24,155M 22,892M 31,774M 41,109M 44,773M
Diluted EPS 72.09 59.01 113.09 117.39 115.14
Dividends Per Share 20 20 20 25 25
Total Assets 219,821M 225,604M 225,427M 232,241M 265,491M
Total liabilities 95,777M 99,144M 85,230M 77,253M 90,510M
Total equity 124,044M 126,460M 140,197M 154,988M 174,981M
Operating cash flow 21,216M 17,110M 27,878M 29,249M 35,602M
 Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021
Revenue 2,099.83M 2,203.14M 2,199.67M 2,462.41M 2,555.69M
Gross Profit 1,096.54M 1,104.28M 1,115.31M 1,242.17M 1,388.52M
Operating income 192.04M 173.45M 280.00M 403.87M 430.75M
Income before tax 213.31M 217.12M 314.61M 246.39M 375.07M
Net income 179.53M 152.11M 268.71M 274.98M 257.95M
EBITDA 360.21M 355.10M 454.28M 579.76M 603.12M
Diluted EPS 1.07 0.91 1.61 1.65 1.55
Dividends Per Share 0.29 0.31 0.28 0.35 0.33
Total Assets 3,385.24M 3,459.03M 3,254.08M 3,069.88M 3,631.20M
Total liabilities 1,474.96M 1,520.10M 1,230.31M 1,021.17M 1,237.93M
Total equity 1,910.27M 1,938.92M 2,023.77M 2,048.71M 2,393.27M
Operating cash flow 316.38M 265.41M 398.58M 412.50M 479.58M

Valuation Measures

Mar 2021
Operating margin16.85%
Profit margin10.09%

Key executives

  • Chief Executive & Operating Officer: Erez Israeli
  • Chief Financial Officer: Parag Agarwal
  • Secretary & Compliance Officer: Sandeep Poddar
  • Executive Vice President & Head-Branded Markets: M. V. Ramana
  • Chief Human Resource Officer & Executive VP: Archana Bhaskar


  • Dr. Reddy's Holdings Ltd. (24.8%)
  • First Sentier Investors (Australia) IM Ltd. (3.5%)
  • SBI Funds Management Pvt Ltd. (2.1%)
  • Aditya Birla Sun Life Amc Ltd. (Investment Management) (1.9%)
  • BlackRock Fund Advisors (1.8%)
  • GIC Pte Ltd. (Investment Management) (1.6%)
  • Life Insurance Corp of India (1.5%)
  • The Vanguard Group, Inc. (1.4%)
  • Mirae Asset Global Investments (India) Pvt Ltd. (1.4%)
  • ICICI Prudential Life Insurance Co. Ltd. (Invt Port) (1.3%)

Contact Details

  • Website:
  • Address: Door No. 8-2-337, Road No. 3, Hyderabad, 500034, India
  • Phone: +91.40.49002900

Related Companies

  • Dr. Reddy's Farmaceutica do Brasil Ltda.
  • Dr. Reddy's Employees ESOS Trust
  • Dr. Reddy's Research Foundation
  • BMS Laboratories Ltd.
  • Wockhardt Ltd. /Domestic Formulations Bus/
  • Imperial Credit Pvt Ltd.
  • Ducere Pharma LLC/Otc Bus/
  • UCB SA /Established Product Bus/
  • Dr. Reddy's Laboratories SA
  • Zenovus Biotech Pvt Ltd.
  • Regkinetics Services Ltd.
  • Dr. Reddy's Bio-Sciences Ltd.
  • Idea2Enterprises (India) Pvt Ltd.
  • Industrias Quimicas Falcon de Mexico SA de CV
  • Kunshan Rotam Reddy Pharmaceutical Co., Ltd.
  • Aurigene Discovery Technologies Ltd.
  • Perlecan Pharma Pvt Ltd.
  • Macred India Pvt Ltd.
  • BASF SE /Pharmaceutical Contract Manufacturing Unit/
  • Dowpharma /Small Molecules Business/
  • Laboratorios Litaphar SA
  • F. Hoffmann-La Roche Ltd. /Drug Ingredient Making Plant/
  • Trigenesis Therapeutics, Inc.
  • OctoPlus N.V.


  • Perrigo Co. Plc
  • KRKA dd
  • Novartis AG
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Limited
  • Glenmark Pharmaceuticals Limited
  • Hikma Pharmaceuticals Plc
  • Takeda Pharmaceutical Co. Ltd.
  • Bayer AG
  • Pfizer Limited
  • Sanofi
  • Lupin Limited
  • Cipla Limited
  • Alkem Laboratories Ltd.
  • Fresenius SE & Co. KGaA
  • Nichi-Iko Pharmaceutical Co., Ltd.
  • Cadila Healthcare Limited
  • Chemical Works of Gedeon Richter Plc
  • STADA Arzneimittel AG
  • Sanofi India Limited
  • Viatris, Inc.
  • GlaxoSmithKline Pharmaceuticals Limited
  • Sun Pharmaceutical Industries Limited
  • Piramal Enterprises Ltd.
  • Abbott India Limited
  • Endo International Plc
  • Hindustan Unilever Limited
  • Lonza Group AG
  • Aurobindo Pharma Ltd
  • Dishman Carbogen Amcis Ltd.
Last Updated on 18 Jun, 2021

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends January 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more